MARA B ANTONOFF to Chemotherapy, Adjuvant
This is a "connection" page, showing publications MARA B ANTONOFF has written about Chemotherapy, Adjuvant.
Connection Strength
0.436
-
Commentary: Is neoadjuvant chemoimmunotherapy for esophageal cancer the next great frontier? J Thorac Cardiovasc Surg. 2024 Aug; 168(2):429-430.
Score: 0.128
-
Commentary: Old Data Provide New Insights Into the Therapeutic Benefit of Adjuvant Chemotherapy in Non-Small Cell Lung Cancer. Semin Thorac Cardiovasc Surg. 2024 Summer; 36(2):271-272.
Score: 0.118
-
Enhanced recovery after thoracic surgery is associated with improved adjuvant chemotherapy completion for non-small cell lung cancer. J Thorac Cardiovasc Surg. 2019 07; 158(1):279-286.e1.
Score: 0.092
-
The coming of age of molecular tumor profiling. Semin Thorac Cardiovasc Surg. 2011; 23(1):8-9.
Score: 0.052
-
Pathological nodal disease defines survival outcomes in patients with lung cancer with tumour major pathological response following neoadjuvant chemotherapy. Eur J Cardiothorac Surg. 2021 01 04; 59(1):100-108.
Score: 0.026
-
Long-Term Survival Outcomes of Cancer-Directed Surgery for Malignant Pleural Mesothelioma: Propensity Score Matching Analysis. J Clin Oncol. 2017 Oct 10; 35(29):3354-3362.
Score: 0.021